Clinical Trials
19 trialsNCT06199557 2025-06-29
HUVAMER
Haukeland University Hospital
Phase 1/2 Recruiting
NCT03885947 2021-05-24
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02124174 2021-04-26
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Loyola University
Phase 2 Unknown
NCT00414310 2019-05-21
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00075010 2018-11-15
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00854581 2018-04-17
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
University of Miami
Phase 4 Terminated
NCT02144623 2017-03-03
PREVAIL
Lund University Hospital
Phase EARLY_PHASE1 Completed
NCT00867672 2016-08-31
DECIDER
University Hospital Freiburg
Phase 2 Completed
NCT00175812 2015-06-24
Differentiation Induction in Acute Myelogenous Leukemia
University of Bergen
Phase 1/2 Completed
NCT00995332 2015-06-24
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
University of Bergen
Phase 1/2 Completed
NCT01369368 2015-06-24
Treatment of Acute Leukemia Relapse After Allotransplantation
University of Bergen
Phase 1/2 Unknown
NCT01016990 2014-01-10
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00079378 2013-09-30
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00382590 2012-08-07
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00326170 2012-06-15
Phase II 5-Azacytidine Plus VPA Plus ATRA
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01295593 2012-06-07
Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 1/2 Unknown
NCT01011998 2011-09-27
A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)
New Mexico Cancer Research Alliance
Phase 2 Withdrawn
NCT00524667 2011-07-20
HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia
CancerCare Manitoba
Phase 2 Terminated
NCT00810680 2008-12-18
Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)
All India Institute of Medical Sciences
Phase NA Unknown